Dr. Elena Spanjaard joined Celyad Oncology in August 2018 as the Global Head of Regulatory Affairs. In May 2020, she assumed responsibility for Quality Assurance in addition to Regulatory Affairs. Prior to joining Celyad Oncology, Elena led global regulatory strategy for the allogeneic CAR T portfolio at Pfizer in collaboration with Servier and Cellectis. During Elena’s time at Pfizer, she specialized in early immuno-oncology and combination development. Elena’s career has spanned all stages of development in a variety of therapeutic areas including oncology, autoimmune and rare diseases. Elena began her Regulatory career in early development of immuno-oncology cell therapies at Dana-Farber Cancer Institute where she developed strong expertise in T cell manufacturing and characterization. Trained in Immunology, Elena earned her PhD from Boston University School of Medicine.